WCG CLINICAL, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | -.--% |
| 2021 | WCG Clinical : GIC-backed clinical trial firm WCG withdraws U.S. IPO plans | RE |
| 2021 | WCG Clinical : GIC-backed clinical trial firm WCG withdraws IPO plans | RE |
| Sales 2019 | 413M 33.05B | Sales 2020 | 463M 37.1B | Capitalization | 6.07B 486B |
|---|---|---|---|---|---|
| Net income 2019 | 18M 1.44B | Net income 2020 | -95M -7.6B | EV / Sales 2019 * | - |
| Net cash position 2019 * | - 0 | Net cash position 2020 * | - 0 | EV / Sales 2020 * | - |
| P/E ratio 2019 * |
-
| P/E ratio 2020 * |
-
| Employees | - |
| Yield 2019 * |
-
| Yield 2020 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Srivastava Sam
CEO | Chief Executive Officer | - | - |
Nicholas Slack
PSD | President | 41 | 30/06/12 |
Ian Neilson
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Baumer
BRD | Director/Board Member | 56 | 31/12/18 |
Eugene Gorbach
BRD | Director/Board Member | 47 | 31/12/11 |
| Director/Board Member | 66 | 31/12/11 |
WCG Clinical Holdings Inc is a United States-based company. The Company is a provider of clinical trial solutions. It is focused on providing solutions that are designed to improve clinical research. Its solutions help biopharmaceutical companies, contract research organizations, and institutions for delivery of new treatments and therapies to patients. It is organized into two segments: Ethical Review (ER) segment and Clinical Trial Solutions segment. The ER segment provides technology-enabled services that ensure clinical trials respect the rights and protect the welfare of patient participants. ER segment also provides a hosted software application to its clients. Clinical Trial Solutions (CTS) segment provides technology-enabled solutions that support the conduct of effective clinical trials, including study planning and site optimization, patient engagement, and scientific and regulatory review.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 6.07B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- WCGC Stock
